AU2019338059B2 - Method of manufacturing a solid form of a bet bromodomain inhibitor - Google Patents

Method of manufacturing a solid form of a bet bromodomain inhibitor Download PDF

Info

Publication number
AU2019338059B2
AU2019338059B2 AU2019338059A AU2019338059A AU2019338059B2 AU 2019338059 B2 AU2019338059 B2 AU 2019338059B2 AU 2019338059 A AU2019338059 A AU 2019338059A AU 2019338059 A AU2019338059 A AU 2019338059A AU 2019338059 B2 AU2019338059 B2 AU 2019338059B2
Authority
AU
Australia
Prior art keywords
compound
solution
cancer
solvent
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019338059A
Other languages
English (en)
Other versions
AU2019338059A1 (en
Inventor
Jiahui Chen
Mark T. Edgar
Henrik C. Hansen
Feng Wen
Xianghui Wen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zenith Epigenetics Ltd
Original Assignee
Zenith Epigenetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenith Epigenetics Ltd filed Critical Zenith Epigenetics Ltd
Publication of AU2019338059A1 publication Critical patent/AU2019338059A1/en
Application granted granted Critical
Publication of AU2019338059B2 publication Critical patent/AU2019338059B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
AU2019338059A 2018-09-13 2019-09-13 Method of manufacturing a solid form of a bet bromodomain inhibitor Active AU2019338059B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862730849P 2018-09-13 2018-09-13
US62/730,849 2018-09-13
PCT/IB2019/001011 WO2020053657A1 (en) 2018-09-13 2019-09-13 Method of manufacturing a solid form of a bet bromodomain inhibitor

Publications (2)

Publication Number Publication Date
AU2019338059A1 AU2019338059A1 (en) 2021-04-01
AU2019338059B2 true AU2019338059B2 (en) 2025-03-20

Family

ID=69777480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019338059A Active AU2019338059B2 (en) 2018-09-13 2019-09-13 Method of manufacturing a solid form of a bet bromodomain inhibitor

Country Status (14)

Country Link
US (2) US12145932B2 (cg-RX-API-DMAC7.html)
EP (2) EP3849980B1 (cg-RX-API-DMAC7.html)
JP (2) JP7731794B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210080373A (cg-RX-API-DMAC7.html)
CN (1) CN112955449B (cg-RX-API-DMAC7.html)
AU (1) AU2019338059B2 (cg-RX-API-DMAC7.html)
CA (1) CA3111527A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190598A1 (cg-RX-API-DMAC7.html)
ES (1) ES3034982T3 (cg-RX-API-DMAC7.html)
IL (1) IL281258B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002885A (cg-RX-API-DMAC7.html)
SG (1) SG11202102497SA (cg-RX-API-DMAC7.html)
TW (1) TWI882964B (cg-RX-API-DMAC7.html)
WO (1) WO2020053657A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882964B (zh) 2018-09-13 2025-05-11 大陸商恒翼生物醫藥(上海)股份有限公司 Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法
TW202327594A (zh) 2021-09-23 2023-07-16 大陸商恒翼生物醫藥(上海)股份有限公司 用bet溴結構域抑制劑和parp抑制劑的組合治療預選患者群體的三陰性乳腺癌的方法
KR102619331B1 (ko) * 2021-11-30 2023-12-29 주식회사 베노바이오 Bet 단백질을 저해하는 신규한 카르복스아마이드 리독스 유도체 및 이를 이용한 안과질환 예방 및 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002754A2 (en) * 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN105473581B (zh) 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
BR122019007990B1 (pt) 2013-11-18 2021-05-04 Forma Therapeutics, Inc Composto, e, composição farmacêutica
CA2966452A1 (en) 2014-12-17 2016-06-23 Samuel David Brown Substituted bicyclic compounds as bromodomain inhibitors
WO2017075377A1 (en) * 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CN109715625B (zh) * 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
WO2018097977A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
TWI816880B (zh) 2018-09-13 2023-10-01 大陸商恒翼生物醫藥(上海)股份有限公司 治療前列腺癌之組合療法
TWI841598B (zh) 2018-09-13 2024-05-11 大陸商恒翼生物醫藥(上海)股份有限公司 用於治療雌激素受體陽性乳癌之組合療法
TWI882964B (zh) 2018-09-13 2025-05-11 大陸商恒翼生物醫藥(上海)股份有限公司 Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002754A2 (en) * 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors

Also Published As

Publication number Publication date
EP4588919A1 (en) 2025-07-23
US20250034142A1 (en) 2025-01-30
EP3849980B1 (en) 2025-04-23
EP3849980A1 (en) 2021-07-21
TW202024078A (zh) 2020-07-01
IL281258B1 (en) 2025-11-01
CN112955449A (zh) 2021-06-11
JP2022500433A (ja) 2022-01-04
KR20210080373A (ko) 2021-06-30
WO2020053657A1 (en) 2020-03-19
US20220048905A1 (en) 2022-02-17
IL281258B2 (en) 2026-03-01
CA3111527A1 (en) 2020-03-19
MX2021002885A (es) 2021-07-15
TWI882964B (zh) 2025-05-11
SG11202102497SA (en) 2021-04-29
US12145932B2 (en) 2024-11-19
AU2019338059A1 (en) 2021-04-01
ES3034982T3 (en) 2025-08-27
JP7731794B2 (ja) 2025-09-01
JP2025179092A (ja) 2025-12-09
CN112955449B (zh) 2025-04-29
EA202190598A1 (ru) 2021-08-02
IL281258A (en) 2021-04-29
EP3849980A4 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
US20250034142A1 (en) Method of manufacturing a solid form of a bet bromodomain inhibitor
WO2020053660A1 (en) Solid forms of a bet inhibitor
TWI697495B (zh) 科帕利普(copanlisib)及其二鹽酸鹽之合成
EP3325485B1 (en) Methods of preparing cytotoxic benzodiazepine derivatives
WO2011116634A1 (en) Process and intermediates for preparing lapatinib
CN114685531B (zh) 四并环化合物及其药物组合物和应用
WO2022214645A1 (en) Processes and intermediates for the preparation of relugolix
AU2018213202B2 (en) Methods of preparing cytotoxic benzodiazepine derivatives
JP7136527B2 (ja) 3-[(3s)-7-ブロモ-2-オキソ-5-(ピリジン-2-イル)-2,3-ジヒドロ-1h-[1,4]-ベンゾジアゼピン-3-イル]プロピオン酸メチルエステルの調製方法及びその方法に有用な化合物
CA2648369A1 (en) Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4?l)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
EA043992B1 (ru) Способ изготовления твердой формы ингибитора бромодомена bet
HK40053356A (en) Method of manufacturing a solid form of a bet bromodomain inhibitor
WO2016071382A1 (en) Synthesis of pi3k inhibitor and salts thereof
HK40053356B (en) Method of manufacturing a solid form of a bet bromodomain inhibitor
EP4538259A1 (en) Processes for the preparation of deucravacitinib
JP7842890B2 (ja) 4-[5-[ビス(2-クロロエチル)アミノ]-1-メチル-1H-ベンゾ[d]イミダゾール-2-イル]酪酸アルキルエステル及びホルミル化誘導体の調製方法
EP4512809A1 (en) Method for producing 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
CN114591247A (zh) 一种替莫唑胺中间体化合物
HK1252323B (en) Methods of preparing cytotoxic benzodiazepine derivatives
WO2016071380A1 (en) Synthesis of pi3k inhibitor and salts thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)